Abstract: The present disclosure is directed to alcohol and amine containing exatecan derivatives, and pharmaceutically acceptable salts or solvates thereof, comprising a structure of formula I: wherein X is defined in the disclosure. The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of cancers and/or tumors.

Abstract: Described herein are compositions and methods for the storage and release of hydrogen gas using covalent organic frameworks (COFs). Advantageously, the compositions and methods described herein may be used for the facile and rapid release of hydrogen gas at near ambient temperatures. The described COFs allow for photoactivation, where the release of gas is initiated or the rate of release is increased with the COF is exposed to electromagnetic radiation, for example, UV light.

Abstract: The current invention relates to a method of separating polyunsaturated fatty acids containing lipids from a lipids containing biomass.

Abstract: A formulation delivery system configured for outdoor use. The formulation delivery system includes a cleaning composition comprising chlorine, wherein the composition is in a form of a solid chemistry, and an outdoor cleaning device that is a spray wand having the cleaning composition positioned within a dispensing cartridge housed within the outdoor cleaning device.

Abstract: A formulation delivery system for use with an outdoor cleaning device is provided. The formulation delivery system has a composition containing chlorine, wherein the composition is in a form of a solid chemistry and the outdoor cleaning device is a spray wand containing the composition. The chlorine is selected from the group consisting of calcium hypochlorite; 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3-dichloro-, sodium salt, dihydrate (dichlor); 1,3,5-Trichloro-1,3,5-triazinane-2,4,6-trione (trichlor), chloramine-T hydrate, and a combination thereof. A spray wand having a refill cartridge for containing the composition in solid form is also provided.

Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: An implant removal device having an elongate body having a proximal end and a distal end, the elongate body being resiliently flexible and configured to transmit torque from the proximal end to the distal end with a predetermined turning ratio, and a capturing structure extending distally from the distal end and having a capture region, the capturing structure being configured to selectively center a deployed implant in relation to a longitudinal axis of the elongate body and the capture region to aid with capture and subsequent removal.

Abstract: Devices, systems and methods for removal of a mitral valve clip and subsequent delivery of a mitral valve implantation in a mitral valve replacement procedure. A modular port accessory device having a distal connector configured to be compatible with corresponding connectors on an existing therapeutic device, wherein the port accessory can be selectively attached to a proximal end portion connector of a proximal end portion of a catheter assembly of an existing therapeutic device. The catheter assembly is introduced to a target site within the patient's anatomy, and remains in place throughout a multistep therapeutic procedure for use with other therapeutic devices, all while allowing hemostasis to be controlled during use ad interchange of multiple therapeutic devices.

Abstract: Techniques are described that determine a user to participate in software testing of a social network application and/or service and to enable the user to propagate an invitation to contacts of the user to participate in the software testing of the social network application. In some examples, the user may be provided a message via an inbox of a first service including the invitation and a selectable option to install an application associated with a second service. In some, examples, the user may be sent a list of contacts from which the user may select other users to also participate in the software testing of the social network application. In some examples, responsive to the user's selection, a message may be sent to an inbox of the selected contacts that contains an invitation to participate in the beta version of the social network application.

Abstract: A formulation delivery system for use with an outdoor cleaning device is provided. The formulation delivery system has a composition containing chlorine, wherein the composition is in a form of a solid chemistry and the outdoor cleaning device is a spray wand containing the composition. The chlorine is selected from the group consisting of calcium hypochlorite; 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3-dichloro-, sodium salt, dihydrate (dichlor); 1,3,5-Trichloro-1,3,5-triazinane-2,4,6-trione (trichlor), chloramine-T hydrate, and a combination thereof. A spray wand having a refill cartridge for containing the composition in solid form is also provided.

Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.

Abstract: Techniques are described that determine a user to participate in software testing of a social network application and/or service and to enable the user to propagate an invitation to contacts of the user to participate in the software testing of the social network application. In some examples, the user may be provided a message via an inbox of a first service including the invitation and a selectable option to install an application associated with a second service. In some, examples, the user may be sent a list of contacts from which the user may select other users to also participate in the software testing of the social network application. In some examples, responsive to the user's selection, a message may be sent to an inbox of the selected contacts that contains an invitation to participate in the beta version of the social network application.

Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) e a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact

Abstract: The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-conta

Abstract: Methods, devices and systems for disabling and/or removing a mitral valve edge-to-edge repair device via minimally invasive, endovascular procedures. Additional procedures on a heart may sometimes become necessary after the installation of a mitral valve edge-to-edge repair device. To prepare for such additional procedures, the edge-to-edge repair device may be removed or disabled in minimally invasive ways (e.g., through an endovascular procedure), without requiring open access to the heart.